Drug Discovery and Development Solutions for Endometriosis

Our In Vitro Efficacy Testing Service accelerates endometriosis drug discovery by providing robust, high-throughput screening and characterization platforms. We utilize advanced biochemical and cell-based assays—including luminescent, fluorescent, radiometric, RNA-based, and binding assays—to evaluate compound potency, mechanism of action, and target engagement. Key endpoints include EC-50, IC-50, Kd, and MIC for critical targets such as estrogen and progesterone receptors, cytokines, and steroidogenic enzymes. Our comprehensive approach delivers precise, actionable data on pharmacological profiles, supporting informed decision-making and efficient lead optimization in preclinical research for endometriosis therapeutics.

Ace Therapeutics provides comprehensive in vivo endometriosis animal model development, supporting preclinical efficacy, mechanism-of-action, and safety studies. Utilizing 38 validated models across five species and eleven strains, we offer surgically-induced, chemically-induced, genetically engineered, and xenograft/allograft methodologies. Services include model selection, custom protocol design, surgical induction, and advanced endpoint analysis—covering lesion assessment, pain behavior, biomarker quantification, fertility, and imaging. Our rigorous quality control, expert veterinary oversight, and advanced analytical platforms ensure reliable, translationally relevant data. Partner with Ace Therapeutics to accelerate endometriosis research and therapeutic development through scientifically robust, tailored animal modeling solutions.

Our PK/PD research service for Endometriosis offers comprehensive analysis of drug exposure and therapeutic response using advanced analytical methods such as HPLC-MS and LC-MS. We assess multiple administration routes and biological compartments, including plasma, uterus, and tumor tissue, to optimize bioavailability and tissue targeting. Employing diverse animal models, we generate translational data on ADME and concentration-effect relationships, supporting dosing optimization and interspecies scaling. Our integrated approach enables informed decision-making in drug development, accelerating the transition from preclinical validation to clinical application, and ultimately enhancing the success of Endometriosis therapeutic candidates.

Ace Therapeutics delivers comprehensive in vivo toxicity assessment services tailored for endometriosis drug development. Utilizing advanced methodologies, validated animal models, and state-of-the-art analytics, we conduct acute, chronic, organ-specific, reproductive, and neurobehavioral toxicity studies. Our GLP-compliant approach ensures robust data integrity and regulatory acceptance. Specialized endpoints such as uterine morphology and hormonal profiling address disease-specific safety concerns. Integration with pharmacokinetic and efficacy data provides a holistic safety profile, supporting informed decision-making. With a multidisciplinary team and rigorous quality control, Ace Therapeutics empowers clients to advance novel therapeutics with confidence in both safety and therapeutic potential.

Ace Therapeutics offers exploratory biomarker analysis services supporting preclinical Endometriosis research. We utilize multi-omics discovery approaches—including genomics, transcriptomics, proteomics, and metabolomics—to investigate molecular signatures and assess the potential of candidate biomarkers. Our screening and evaluation methodologies employ advanced analytical platforms such as immunoassays, mass spectrometry, cytometry, molecular, and imaging techniques. We explore the relevance of molecular targets to Endometriosis pathophysiology, emphasizing robust assay development, rigorous validation protocols, and quantitative analysis. Our technical expertise enables comprehensive evaluation of biomarkers with potential research utility, while maintaining scientific objectivity and adhering strictly to preclinical, non-diagnostic research applications.